All News
Active early RA accentuates regional MSK pain.
Non-articular pain:
easy to ignore & focus on active RA
yes, some is related to RA dx activity
BUT actually it becomes a bigger issue over time
Worth identifying to:
clarify what isn't RA
Rx appropriately
#ACR24 ABST1335 @RheumNow https://t.co/iN5rsyr7Bx
David Liew drdavidliew ( View Tweet)
ACR 2024 - Day 2 Report
Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.
Read Article
I've shared some further thoughts on @jeffsparks SAIL-RA study and its finding of the strong association of RA-ILD with disease activity in early RA. And of course couldn't resist going on a tangent about the ACR ILD guidelines! #ACR24 @RheumNow https://t.co/UUDbWw38Im
Richard Conway RichardPAConway ( View Tweet)
A key practice changing study (I hope) from #ACR24 has been the preCARA study. Fertility increases with aggressive disease control. My video on this study is up now on @RheumNow https://t.co/Pf3rdTHbOJ
Richard Conway RichardPAConway ( View Tweet)
VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Would be helpful for us (and pts) to better understand rimmunotherapy agent specific risk on subsequent GCA/PMR
AFTRER propensity matching of >7k pt on combo nivolumab/ipilimumab compared to pembrolizumab:
- PMR RR 3.8x N/I vs. P
- no diff in GCA risk
@RheumNow #ACR24 https://t.co/IF4Gh7Cumd
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
🔶Clinical Year in Review #ACR24 🔶
Talk By @MHPillingerMD
• Review some of the most impactful studies in Rheumatology from the past year!
#RheumTwitter #Rheumatology https://t.co/1ULDB2l4gX
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
Older RA patients in RISE with high disease activity show a higher incidence of hip and major osteoporotic fractures. Practice T2T and monitor bone health closely!
#ACR24 @RheumNow ABST#1748 https://t.co/7MCAIrfXhp
Jiha Lee JihaRheum ( View Tweet)
RCTs are the gold standard in drug research, but rising placebo (PBO) response rates with global recruitment could distort treatment effects. Limited access to care in less affluent countries may be a factor.
#ACR24 @RheumNow ABST#1746 https://t.co/fVeNcw5qwO
Jiha Lee JihaRheum ( View Tweet)
SURPASS trial of bio naïve axSpA at risk of radiographic progression:
1. Presence of syndesmophytes
2. Higher CRP levels
3. Higher ASDAS
4. Higher spinal MRI BME scores
Were predictors of spinal progression independent of ttnt
Abst#1759 #ACR24 @RheumNow https://t.co/QC9FMPufPY
Adela Castro AdelaCastro222 ( View Tweet)
How does #race & #ethnicity impact mortality in RA?
Study in CDC national mortality database
➡️RA mortality differed by race & ethnicity
➡️Highest premature mortality in Native Americans
Findings may be used to inform resource allocation & management
Ab1747 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Andreasson et al. High intensity interval training provides greater improvements in exercise capacity than standard moderate intensity training in IIM. @RheumNow #ACR24 Abstr#1735 https://t.co/baj7Cq2QjO https://t.co/yiE1vuk2me
Richard Conway RichardPAConway ( View Tweet)
Andreasson et al. High intensity interval training provides greater improvements in exercise capacity than standard moderate intensity training in IIM. @RheumNow #ACR24 Abstr#1735 https://t.co/baj7Cq2QjO https://t.co/yiE1vuk2me
Richard Conway RichardPAConway ( View Tweet)
A#1748
Fracture incidence in RA - RISE registry
Incidence rate of MOF, hip Fx by disease activity
50% did not have CDAI available
IR 12 per 1000py hip, 43 for MOF
High activity worst, low/mod similar, remission is best
Supports remission is better than LDA
@RheumNow #ACR24 https://t.co/78FCLemfZD
Eric Dein ericdeinmd ( View Tweet)
Can we do more to routinely assess fracture risk in RA?
In RA pts ≥65, hip fracture & MOF are more common in pts with active disease, worse with higher disease activity
➡️Need better and more frequent bone health assessments in our RA pts
Ab1748 #ACR24 @RheumNow https://t.co/whfnLnkpLd
Mrinalini Dey DrMiniDey ( View Tweet)
A#1747
RA mortality by race/ethnicity
Database study
>200,000 pts had RA as contributing cause of death
5.1 ASMR in American Indian >>> all other groups
No decr over time in grp, unlike other grps
Odds of death 1.67 compared to white pop
10.8x higher in pts <44
#ACR24 @RheumNow https://t.co/nXLcQkQPu4
Eric Dein ericdeinmd ( View Tweet)
A#1746 companion for RA
Like plenary for PsA, PBO response incr w time 1%/yr
More trials in less affluent countries may be related to increasing PBO response in trials
Possible reason: access to health care improves PBO in less affluent areas
@RheumNow #ACR24 https://t.co/S3LffF8vPH
Eric Dein ericdeinmd ( View Tweet)
RA patients on TOF with h/o ASCVD have 4x higher risk of MACE without statin (vs. TNFi).
Prioritize statins for heart health in RA!
#ACR24 @RheumNow ABST#1745 https://t.co/jRqXNU2T6d
Jiha Lee JihaRheum ( View Tweet)
Wallace et al. Case control study. 648 cases 1241 controls. Cumulative glucocorticoid dose and risk MACE. Dose dependent increase in risk, OR 1.01 for 10% increase GC, 1.21 for 10-fold increase GC. @RheumNow #ACR24 Abstr#1719 https://t.co/wraiWOl1dv https://t.co/feht58RDNc
Richard Conway RichardPAConway ( View Tweet)
Wallace et al. Case control study. 648 cases 1241 controls. Cumulative glucocorticoid dose and risk MACE. Dose dependent increase in risk, OR 1.01 for 10% increase GC, 1.21 for 10-fold increase GC. @RheumNow #ACR24 Abstr#1719 https://t.co/wraiWOl1dv https://t.co/feht58RDNc
Richard Conway RichardPAConway ( View Tweet)